Myoscint moves closer to approval:
This article was originally published in Clinica
Executive Summary
The US FDA's Cardiovascular and Renal Drugs Advisory Committee has recommended approval for Centocor's heart attack imaging agent, Myoscint. Mallinckrodt Medical already distributes Myoscint in Europe and a product licence application is under review in Japan. Centocor will market the imaging agent, an (111-)In-labelled anti-myosin heavy chain antibody, in the US.